TABLE 3.
AGA-suggested Target Ctrough for Reactive TDM in Patients With Active IBD on Anti-TNF Maintenance Therapy17
| Drug | Suggested Target Ctrough (µg/mL) |
|---|---|
| Infliximab | ≥5 |
| Adalimumab | ≥7.5 |
| Golimumab | Unknown |
| Certolizumab pegol | ≥20 |
AGA indicates American Gastroenterological Association; Ctrough, trough concentration; IBD, inflammatory bowel disease; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor.